Literature DB >> 23680059

Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND.

Elizabeth R Seaquist1, Michael E Miller, Vivian Fonseca, Faramarz Ismail-Beigi, Lenore J Launer, Zubin Punthakee, Ajay Sood.   

Abstract

OBJECTIVE: To examine the relationship of cognitive performance to exposure to insulin (INS) and thiazolidinediones (TZD) in the ACCORD-MIND cohort.
METHODS: Participants (55-80years) with type 2 diabetes (T2D), hemoglobin A1c (HbA1c) >7.5% (>58mmol/mol), and a high risk of cardiovascular events were randomly assigned to receive intensive control targeting HbA1c to <6.0% (42mmol/mol) or a standard strategy targeting HbA1c to 7.0%-7.9% (53-63mmol/mol). The Digit Symbol Substitution Test (DSST) was assessed at baseline and at 20 and 40months. Exposure to INS was calculated as average daily dose/kg of body weight; exposure to rosiglitazone (ROS) was calculated as days of ROS prescription in the intervals preceding the 20- and 40-month DSSTs.
RESULTS: At baseline, INS use was associated with reduced DSST performance, but not after controlling for comorbidities and lab values. There was no relationship between use of a TZD and DSST performance on at baseline. ROS but not INS exposure was associated with greater decline in DSST performance over 40months in subjects randomized to the intensive but not the standard group.
CONCLUSIONS: Exposure to a TZD may increase cognitive decline in some patients with T2D. However, these results may be confounded by unexplained differences between participants.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition; Diabetes; Insulin; Thiazolidinediones

Mesh:

Substances:

Year:  2013        PMID: 23680059      PMCID: PMC3748242          DOI: 10.1016/j.jdiacomp.2013.03.005

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  16 in total

1.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

2.  Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies.

Authors:  Cécile Proust-Lima; Hélène Amieva; Jean-François Dartigues; Hélène Jacqmin-Gadda
Journal:  Am J Epidemiol       Date:  2006-11-14       Impact factor: 4.897

3.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.

Authors:  G Stennis Watson; Brenna A Cholerton; Mark A Reger; Laura D Baker; Stephen R Plymate; Sanjay Asthana; Mark A Fishel; J Jacob Kulstad; Pattie S Green; David G Cook; Steven E Kahn; Michelle L Keeling; Suzanne Craft
Journal:  Am J Geriatr Psychiatry       Date:  2005-11       Impact factor: 4.105

Review 4.  Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.

Authors:  Suzanne Craft
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

5.  Performance on the digit symbol substitution test and 5-year mortality in the Western Collaborative Group Study.

Authors:  G E Swan; D Carmelli; A LaRue
Journal:  Am J Epidemiol       Date:  1995-01-01       Impact factor: 4.897

6.  Age-related slowing of digit symbol substitution revisited: what do longitudinal age changes reflect?

Authors:  Stuart W S MacDonald; David F Hultsch; Esther Strauss; Roger A Dixon
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2003-05       Impact factor: 4.077

7.  Relation between cognitive function and mortality in middle-aged adults: the atherosclerosis risk in communities study.

Authors:  Valory N Pavlik; Suzana Alves de Moraes; Moyses Szklo; David S Knopman; Thomas H Mosley; David J Hyman
Journal:  Am J Epidemiol       Date:  2003-02-15       Impact factor: 4.897

8.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

9.  Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment.

Authors:  Angela M Abbatecola; Fabrizia Lattanzio; Anna M Molinari; Michele Cioffi; Luigi Mansi; Pierfrancesco Rambaldi; Luigi DiCioccio; Federico Cacciapuoti; Raffaele Canonico; Giuseppe Paolisso
Journal:  Diabetes Care       Date:  2010-04-30       Impact factor: 19.112

10.  Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data.

Authors:  Denise E Bonds; Michael E Miller; Jim Dudl; Mark Feinglos; Faramarz Ismail-Beigi; Saul Malozowski; Elizabeth Seaquist; Debra L Simmons; Ajay Sood
Journal:  BMC Endocr Disord       Date:  2012-05-30       Impact factor: 2.763

View more
  7 in total

1.  The impact of glucose disorders on cognition and brain volumes in the elderly: the Sydney Memory and Ageing Study.

Authors:  Katherine Samaras; Helen L Lutgers; Nicole A Kochan; John D Crawford; Lesley V Campbell; Wei Wen; Melissa J Slavin; Bernard T Baune; Darren M Lipnicki; Henry Brodaty; Julian N Trollor; Perminder S Sachdev
Journal:  Age (Dordr)       Date:  2014-01-09

2.  Expert Consensus on Cognitive Dysfunction in Diabetes.

Authors:  Yan Yang; Jia-Jun Zhao; Xue-Feng Yu
Journal:  Curr Med Sci       Date:  2022-03-15

3.  The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors.

Authors:  Insa Feinkohl; Jackie F Price; Mark W J Strachan; Brian M Frier
Journal:  Alzheimers Res Ther       Date:  2015-06-10       Impact factor: 6.982

Review 4.  Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.

Authors:  Ye-Fong Du; Horng-Yih Ou; Elizabeth A Beverly; Ching-Ju Chiu
Journal:  Clin Interv Aging       Date:  2014-11-18       Impact factor: 4.458

Review 5.  Diabetes and the brain: issues and unmet needs.

Authors:  Natan M Bornstein; Michael Brainin; Alla Guekht; Ingmar Skoog; Amos D Korczyn
Journal:  Neurol Sci       Date:  2014-04-29       Impact factor: 3.307

Review 6.  Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review.

Authors:  Young Sup Woo; Hyun Kook Lim; Sheng-Min Wang; Won-Myong Bahk
Journal:  Int J Mol Sci       Date:  2020-09-22       Impact factor: 5.923

7.  Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.

Authors:  Che-Yuan Wu; Michael Ouk; Yuen Yan Wong; Natasha Z Anita; Jodi D Edwards; Pearl Yang; Baiju R Shah; Nathan Herrmann; Krista L Lanctôt; Moira K Kapral; Bradley J MacIntosh; Jennifer S Rabin; Sandra E Black; Walter Swardfager
Journal:  Alzheimers Dement       Date:  2020-08-16       Impact factor: 16.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.